S.VincentRajkumarMDFRCPC

PubMed

• Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures.
  Saurabh Zanwar, Morie A Gertz, Eli Muchtar, Francis K Buadi, Taxiarchis Kourelis, Wilson Gonsalves, Ronald S Go, Suzanne Hayman, Prashant Kapoor, Moritz Binder, Josell...> ;Leukemia. 2024 Apr 9
• Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide.
  Utkarsh Goel, Charalampos Charalampous, Prashant Kapoor, Moritz Binder, Francis K Buadi, David Dingli, Angela Dispenzieri, Amie Fonder, Morie A Gertz, Wilson I Gonsalv...> ;Blood Cancer Journal. 2024 Mar 26
• Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis.
  Adeel M Khan, Georgia McCaughan, Xiaoliang Wang, James Roose, Larry D Anderson Jr, Fieke W Hoff, Rahul Banerjee, Bo Wang, Andrew J Cowan, S Vincent Rajkumar, Gurbakhas...> ;Blood Cancer Journal. 2024 Mar 22
• Patient-Reported Adverse Events and Early Treatment Discontinuation Among Patients With Multiple Myeloma.
  John Devin Peipert, Fengmin Zhao, Ju-Whei Lee, Shu-En Shen, Edward Ip, Nathaniel O'Connell, Ruth C Carlos, Noah Graham, Mary Lou Smith, Ilana F Gareen, Pamela J Raper,...> ;JAMA Network Open. 2024 Mar 4
• Phase III randomized trial of Thal+ZLD versus ZLD in patients with asymptomatic multiple myeloma - updated results after 18-year follow-up.
  Nadine Abdallah, Thomas E Witzig, Shaji K Kumar, Martha Q Lacy, Suzanne R Hayman, Angela Dispenzieri, Vivek Roy, Morie A Gertz, P Leif Bergsagel, S Vincent Rajkumar> ;Leukemia. 2024 Feb 28
• Mode of progression in smoldering multiple myeloma: a study of 406 patients.
  Abdallah, N., Lakshman, A., Kumar, S., Cook, J., Binder, M., Kapoor, P., Dispenzieri, A., Gertz, M., Lacy, M., Hayman, S., Buadi, F., Dingli, D., Lin, Y., Kourelis, T....> ;Blood Cancer Journal. 2024 Jan 17
• 1 citations
  Superior detection rate of plasma cell FISH using FACS-FISH.
  Gagnon, M., Midthun, S., Fangel, J., Schuh, C., Luoma, I., Pearce, K., Meyer, R., Ailawadhi, S., Arribas, M., Braggio, E., Fonseca, R., Rajkumar, S., Zepeda-Mendoza, C...> ;American Journal of Clinical Pathology. 2024 Jan 4
• Smoldering Multiple Myeloma: Observation Versus Control Versus Cure.
  Bergsagel, P., Rajkumar, S., Kumar, S.> ;Hematology/oncology Clinics of North America. 2024 Apr 1
• Muscle and fat composition in patients with newly diagnosed multiple myeloma.
  Abdallah, N., Nagayama, H., Takahashi, N., Gonsalves, W., Fonder, A., Dispenzieri, A., Dingli, D., Buadi, F., Lacy, M., Hobbs, M., Gertz, M., Binder, M., Kapoor, P., W...> ;Blood Cancer Journal. 2023 Dec 12
• Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma.
  Charalampous, C., Goel, U., Kapoor, P., Binder, M., Buadi, F., Cook, J., Dingli, D., Dispenzieri, A., Fonder, A., Gertz, M., Gonsalves, W., Hayman, S., Hobbs, M., Hwa,...> ;Blood Cancer Journal. 2023 Dec 11
• Discarded Treatments: When the Problem and the Solution Are More Than Meets the Eye.
  Sandahl, T., Rajkumar, S.> ;Mayo Clinic Proceedings. 2023 Dec 1
• Predictors and Impact of Timing of Disease Progression Following Primary Therapy in Multiple Myeloma.
  Sarah Goldman-Mazur, Alissa Visram, S Vincent Rajkumar, Prashant Kapoor, Angela Dispenzieri, Martha Q Lacy, Morie A Gertz, Francis K Buadi, Suzanne R Hayman, David Din...> ;Clinical Lymphoma, Myeloma & Leukemia. 2024 Mar 1
• 2 citations
  Once-weekly bortezomib as the standard of care in multiple myeloma: results from an international survey of physicians.
  Rahul Banerjee, Bo Wang, Larry D Anderson Jr, Georgia McCaughan, Nikita Mehra, Andrew J Cowan, S Vincent Rajkumar, Gurbakhash Kaur> ;Blood Cancer Journal. 2023 Nov 6
• Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE-MM2...
  Paul G Richardson, Thierry Facon, Christopher P Venner, Nizar J Bahlis, Fritz Offner, Darrell White, Lionel Karlin, Lotfi Benboubker, Eric Voog, Sung-Soo Yoon, Kenshi ...> ;Ejhaem. 2023 Nov 1
• Mode of Progression in Smoldering Multiple Myeloma: A study of 406 patients.
  S Rajkumar, Nadine Abdallah, Arjun Lakshman, Shaji Kumar, Joselle Cook, Moritz Binder, Prashant Kapoor, Angela Dispenzieri, Morie Gertz, Martha Lacy, Suzanne Hayman, F...> ;Research Square. 2023 Oct 23
• 1 citations
  Identification of novel genetic loci for risk of multiple myeloma by functional annotation.
  Angelica Macauda, Klara Briem, Alyssa Clay-Gilmour, Wendy Cozen, Asta Försti, Matteo Giaccherini, Chiara Corradi, Juan Sainz, Yasmeen Niazi, Rob Ter Horst, Yang Li, Mi...> ;Leukemia. 2023 Nov 1
• Correction: "The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms" Leukemia. 2022 Jul;36(7):1720-1748.
  Rita Alaggio, Catalina Amador, Ioannis Anagnostopoulos, Ayoma D Attygalle, Iguaracyra Barreto de Oliveira Araujo, Emilio Berti, Govind Bhagat, Anita Maria Borges, Dani...> ;Leukemia. 2023 Sep 1
• Current approach to Waldenström macroglobulinemia.
  Prashant Kapoor, S Vincent Rajkumar> ;Blood Reviews. 2023 Nov 1
• Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy.
  Charalampos Charalampous, Utkarsh Goel, Prashant Kapoor, Moritz Binder, Francis K Buadi, Joselle Cook, David Dingli, Angela Dispenzieri, Amie L Fonder, Morie A Gertz, ...> ;Blood Advances. 2023 Aug 22
• 1 citations
  Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas.
  Udit Yadav, Shaji K Kumar, Linda B Baughn, Angela Dispenzieri, Patricia Greipp, Rhett Ketterling, Dragan Jevremovic, Francis K Buadi, David Dingli, Martha Q Lacy, Rafa...> ;Blood. 2023 Nov 30
• 5 citations
  Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma.
  Saurabh Zanwar, Matthew Ho, Yi Lin, Prashant Kapoor, Moritz Binder, Francis K Buadi, Angela Dispenzieri, David Dingli, Amie Fonder, Morie A Gertz, Wilson Gonsalves, Su...> ;American Journal of Hematology. 2023 Oct 1
• 6 citations
  Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group.
  Meletios A Dimopoulos, Giampaolo Merlini, Frank Bridoux, Nelson Leung, Joseph Mikhael, Simon J Harrison, Efstathios Kastritis, Laurent Garderet, Alessandro Gozzetti, N...> ;The Lancet. Oncology. 2023 Jul 1
• A phase 1/2 of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma (CARAMEL).
  Alissa Visram, Suzanne R Hayman, Angela Dispenzieri, Prashant Kapoor, Martha Q Lacy, Morie A Gertz, Francis K Buadi, David Dingli, Rahma Warsame, Taxiarchis Kourelis, ...> ;American Journal of Hematology. 2023 Aug 1
• Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy.
  Charalampos Charalampous, Utkarsh Goel, Prashant Kapoor, Moritz Binder, Francis K Buadi, Joselle Cook, David Dingli, Angela Dispenzieri, Amie L Fonder, Morie A Gertz, ...> ;Blood Advances. 2023 Aug 22
• Defining Myeloma and Advancing Treatment Options: A Conversation Between S. Vincent Rajkumar and Lale Kostakoglu.
  S Vincent Rajkumar, Lale Kostakoglu> ;Journal of Nuclear Medicine. 2023 Jun 1
• Join now to see all

Journal Articles

• Impact of Prior Diagnosis of Monoclonal Gammopathy on Outcomes in Newly Diagnosed Multiple Myeloma  
  S Vincent Rajkumar, Yi L Hwa, Wilson I Gonsalves, Francis K Buadi, Angela Dispenzieri, Prashant Kapoor, Miriam A Hobbs, Martha Q Lacy, John A Lust, Robert A Kyle, Mori..., Nature
• Relapse After Complete Response in Newly Diagnosed Multiple Myeloma: Implications of Duration of Response and Patterns of Relapse  
  Angela Dispenzieri, Francis K Buadi, Morie A Gertz, Martha Q Lacy, Nelson Leung, Amie L Fonder, Wilson I Gonsalves, Yi Lisa Hwa, Taxiarchis Kourelis, Surbhi Sidana, Ro..., Nature
• Primary Systemic Amyloidosis in Patients with Waldenström Macroglobulinemia  
  Angela Dispenzieri, Eli Muchtar, Ronald Go, Saurabh Zanwar, Surbhi Sidana, Francis Buadi, Stephen M Ansell, Prashant Kapoor, David Dingli, Thomas Habermann, Shaji Kuma..., Nature
• Optimizing Deep Response Assessment for AL Amyloidosis Using Involved Free Light Chain Level at End of Therapy: Failure of the Serum Free Light Chain Ratio  
  Morie A Gertz, David Dingli, Miriam Hobbs, John A Lust, Ronald S Go, Amie Fonder, Yi Lin, Shaji K Kumar, Prashant Kapoor, Taxiarchis V Kourelis, S Vincent Rajkumar, Ro..., Nature
• Risk of MGUS in Relatives of Multiple Myeloma Cases by Clinical and Tumor Characteristics  
  Robert A Kyle, S Vincent Rajkumar, Alexandra J Greenberg, Abdul Rishi, Shaji Kumar, Nature
• Utilization of Hematopoietic Stem Cell Transplantation for the Treatment of Multiple Myeloma: A Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consen...  
  John A Lust, Shaji K Kumar, Morie A Gertz, P Leif Bergsagel, Angela Dispenzieri, Francis K Buadi, Prashant Kapoor, Angela A Mayo, Wilson I Gonsalves, Rafael Fonseca, R..., Nature
• Join now to see all

Books/Book Chapters

• Cecil Textbook of Medicine 
  Chapter: Plasma Cell Disorders 
  Rajkumar SVElsevierEdition 25th,2016
• Multiple Myeloma: Diagnosis and Treatment 
  Morie A. Gertz, S. Vincent Rajkumar (eds)Springer2013
• Abeloff's Clinical Oncology 
  Chapter: Multiple Myeloma and Related Disorders 
  S. Vincent RajkumarElsevierEdition 5th,2013
• Wintrobe's Clinical Hematology 
  Chapter: Monoclonal Gammopathies of Undetermined Significance and Smoldering Multiple Myeloma 
  S. Vincent Rajkumar, Robert A. Kyle, John A. LustWolters Kluvers/ Lippincott Williams & WilkinsEdition 13th,2013
• Amyloidosis: Diagnosis and Treatment 
  Morie A. Gertz, S. Vincent Rajkumar (eds)Humana Press2010
• Oxford Textbook of Medicine 
  Chapter: Myeloma and Paraproteinaemias 
  Robert A. Kyle, S. Vincent RajkumarOxford University Press2010
• Treatment of Multiple Myeloma and Related Disorders 
  S. Vincent Rajkumar, Robert A. Kyle (eds)Cambridge University Press2009
• Join now to see all

Abstracts/Posters

• Utilizing Multiparametric Flow Cytometry to Identify Patients with Primary Plasma Cell Leukemia at Diagnosis
  S. Vincent Rajkumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma
  Vincent Rajkumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Waldenstr_m Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?
  S. Vincent Rajkumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Optimal Therapy for Relapsed AL Amyloidosis Post Autologous Stem Cell Transplant
  S. Vincent Rajkumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients with Newly Diagnosed Multiple Myeloma
  S. Vincent Rajkumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Gene Expression Profiling of Structural and Functional High-Risk Multiple Myeloma
  S. Vincent Rajkumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Prospective Pilot Study of Ixazomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed or Relapsed/Refractory POEMS Syndrome
  S.Vincent Rajkumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients with Newly Diagnosed Multiple Myeloma
  S. Vincent Rajkumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Mortality of Patients with Multiple Myeloma after the Introduction of Novel Therapies in the United States
  S. Vincent Rajkumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Association between a Polygenic Risk Score for Multiple Myeloma Risk and Overall Survival
  S. Vincent Rajkumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Impact of sFLC Ratio on Outcome in Patients with MM: Validating the Utility of sFLC in Response Definition
  S. Vincent Rajkumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Germline Variation Predicts Treatment Response in Multiple Myeloma
  S. Vincent Rajkumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Metaphase Cytogenetics for Risk Stratification in Newly Diagnosed Multiple Myeloma
  S. Vincent Rajkumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Immunological Consequences of Lenalidomide with and without Dexamethasone in Newly Diagnosed Multiple Myeloma
  S.Vincent Rajkumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Prognostic Implications of Serum Monoclonal Protein Positivity By Mass-Fix in Bone Marrow Minimal Residual Disease Negative (MRD-) Patients with Multiple Myeloma
  S. Vincent Rajkumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Patient Experience of Chimeric Antigen Receptor (CAR)-T Cell Therapy Vs. Stem Cell Transplant: Longitudinal Patient Reported Adverse Events, Cognition and Quality of Life
  S. Vincent Rajkumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Novel Approach to Risk Stratification in Multiple Myeloma Using ISS Stage and FISH
  S.Vincent Rajkumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• The CCND1 870G Risk Allele Is Enriched in African Individuals with Plasma Cell Dyscrasias
  S.Vincent Rajkumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Approaches To Achieve the Best Possible Outcomes in Myeloma 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Bortezomib, Lenalidomide and Dexamethasone (VRD) Followed By Autologous Stem Cell Transplant for Newly Diagnosed Multiple Myeloma; The Mayo Clinic Experience 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Longer Term Follow up of the  Randomized Phase III Trial SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) w... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Development of Thrombocytopenia and Survival Outcomes in Newly Diagnosed Multiple Myeloma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Long-Term Survivorship with Active Multiple Myeloma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• New Strategies for Multiple Myeloma Care: Next Steps for The Future 
  60th American Society of Hematology Annual Meeting - 11/30/2018
• Debate: Value and Cost of Myeloma Therapy—We Cannot Afford It 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
• Join now to see all